SAN DIEGO, CA, ADARx Pharmaceuticals, a clinical stage biotechnology company, announced the close of a $46 million Series B-1 financing.
ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company's first product enters the clinic.
The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital all participating in the financing.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
